Chronic obstructive pulmonary disease: a cardiologist’s point of view

2014 ◽  
Vol 155 (37) ◽  
pp. 1480-1484
Author(s):  
Réka Faludi
Keyword(s):  
Heart Failure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Cardiovascular Diseases ◽  
Ischemic Heart Disease ◽  
Pulmonary Disease ◽  
Point Of View ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease is often associated with cardiovascular diseases, such as pulmonary hypertension, ischemic heart disease, arrhythmias or heart failure. These co-morbidities may cause diagnostic or therapeutic difficulties and significantly worsen the morbidity and mortality of patients with chronic obstructive pulmonary disease. In this work the author reviews special considerations for the treatment of patients with chronic obstructive pulmonary disease who have cardiovascular co-morbidities. Orv. Hetil., 2014, 155(37), 1480–1484.

Abstract 14099: Beta-blockers Reduce Mortality in Patients With Heart Failure or Ischemic Heart Disease and Chronic Obstructive Pulmonary Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Mohammed Ruzieh ◽  
Aaron Baugh ◽  
lama jebbawi ◽  
Andrew J Foy
Keyword(s):  
Heart Failure ◽  
Chronic Obstructive Pulmonary Disease ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Beta Blockers ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Risk Of Mortality ◽  
Patients With Heart Failure ◽  
Reduced Risk

Introduction: In patients with heart failure (HF) and ischemic heart disease (IHD), beta-blockers (BB) are associated with improved mortality. However, in patients with co-morbid chronic obstructive pulmonary disease (COPD), this drug class is less utilized due to concerns about an unfavorable impact on the morbidity and mortality. Patients with COPD and heart disease have higher mortality than those with heart disease alone. There is a need to clarify the safety of BB in this population. Objective: To assess the effect of BB therapy on mortality in patients with heart disease and COPD. Methods: We performed a systematic search of MEDLINE and PubMed inception until May 30, 2020 to identify articles of BB use in patients with COPD. The risk ratio (RR) of mortality with BB use was calculated using the Mantel Haenszel random effect model. Statistical analysis was performed using Review Manager Web (RevMan Web). A two-sided p value of < 0.05 was considered statistically significant. Results: A total of 16 studies were included in this meta-analysis, comprising 133,538 patients (44,893 received BB, 88,381 received no control drug, and 264 received placebo). BB use was associated with reduced risk of mortality overall (14.8% vs. 19.9%, RR: 0.67, 95% CI: 0.57 - 0.79), in patients with IHD (18.6% vs. 26.6%, RR: 0.64, 95% CI: 0.50 - 0.82), and in patients with HF (8.1% vs. 23.6%, RR: 0.56, 95% CI: 0.41 - 0.75), Figure. BB were used to treat hypertension in one study, and it was associated with reduced risk of mortality (6.2% vs. 13.4%, RR: 0.46, 95% CI: 0.28 - 0.78). In contrast, βB use was not associated with statistically significant reduced risk of mortality when given without a specified cardiovascular indication (25.0% vs. 32.5%, RR: 0.82, 95% CI: 0.59 - 1.15), figure. Conclusion: Beta-blockers are associated with improved mortality in patients with HF or IHD and COPD. A diagnosis of COPD should not preclude treatment with beta-blockers, as previous concerns likely over-stated risk.

Myocardial Revascularization in Patients With Chronic Ischemic Heart Disease Combined With Chronic Obstructive Pulmonary Disease

Kardiologiia ◽  
2016 ◽  
Vol 1_2016 ◽  
pp. 51-55 ◽  
Author(s):  
V.K. Zafiraki Zafiraki ◽  
K.V. Skaletsky Skaletsky ◽  
E.D. Kosmacheva Kosmacheva ◽  
L.V. Shulzhenko Shulzhenko ◽  
J.M. Ramazanov Ramazanov ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Pulmonary Disease ◽  
Myocardial Revascularization ◽  
Ischemic Heart ◽  
Chronic Obstructive ◽  
Chronic Ischemic Heart Disease ◽  
Obstructive Pulmonary Disease
Sign in / Sign up

Export Citation Format

Share Document